# The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s41397-026-00435-z) · 2026-11-15 · Medicine
Page: https://themorning.science/story/the-impact-of-cyp3a5-genotype-on-tacrolimus-pharmacokinetics-in-children-followi-56d494f785c6ed85
Kind: research · Impact: low

## In brief

- A study published in a Nature subject feed examines how CYP3A5 genotype affects tacrolimus pharmacokinetics in children after heart transplant.
- The only source available is the article title and link; no summary or findings were provided.
- Specific results, sample sizes and dosing conclusions cannot be confirmed from the provided sources.

## Why it matters

Tacrolimus is a key immunosuppressant after transplant and its blood levels vary widely between patients, so genotype-based dosing research in children is of interest to pharmacology and clinical science readers.

## Timeline

- 2026-11-15: Article listed in nature.com subject feed

## Coverage

- [The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant](https://www.nature.com/articles/s41397-026-00435-z) — Medical research : nature.com subject feeds, 2026-11-15

Tags: pharmacogenetics, tacrolimus, heart transplant, paediatrics, cyp3a5

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science